Up to now, several MEK inhibitors, including pimasertib, selumetinib, FCN‐159, and HL‐085, have been investigated for their efficacy and safety for NRAS‐mutant melanoma (Figure 2) [160, 161, 162, 163, 164, 165, 166]. Here, NRAS is linked to melanoma.